Table 1.
Baseline clinical characteristics of patients in the low and high TyG index groups.
| Characteristics | Total population | Low TyG index group | High TyG index group | P value |
|---|---|---|---|---|
| (n=1650) | (n=825) | (n=825) | ||
| Age, years | 60.50 ± 10.19 | 61.14 ± 10.34 | 59.85 ± 10.01 | 0.010 |
| Gender, male, n (%) | 1279 (77.5%) | 618 (74.9%) | 661(80.1%) | 0.011 |
| BMI, kg/m2 | 23.26 ± 2.46 | 23.36 ± 2.48 | 23.17 ± 2.43 | 0.118 |
| SBP, mmHg | 126.93 ± 20.74 | 126.46 ± 20.96 | 127.39 ± 20.51 | 0.363 |
| DBP, mmHg | 77.67 ± 11.97 | 77.28 ± 11.87 | 78.06 ± 12.07 | 0.188 |
| Heart rate, bpm | 73.91 ± 12.05 | 73.29 ± 11.96 | 74.53 ± 12.11 | 0.036 |
| Smoking history, n (%) | 928(56.2%) | 494(59.9%) | 434(52.6%) | 0.003 |
| Drinking history, n (%) | 459(27.8%) | 239(29.0%) | 220(26.7%) | 0.297 |
| Family history of CAD, n (%) | 145(8.8%) | 70(8.5%) | 75(9.1%) | 0.664 |
| Initial diagnosis, n (%) | 0.134 | |||
| UA | 976(59.2%) | 492(59.6%) | 484(58.7%) | |
| NSTEMI | 118(7.2%) | 68(8.2%) | 50(6.1%) | |
| STEMI | 556(33.7%) | 265(32.1%) | 291(35.3%) | |
| Medical history, n (%) | ||||
| Hypertension | 886(53.7%) | 434(52.6%) | 452(54.8%) | 0.374 |
| Hyperlipidemia | 180(10.9%) | 54(6.5%) | 126(15.3%) | < 0.001 |
| Renal dysfunction | 14(0.8%) | 7(0.8%) | 7(0.8%) | > 0.999 |
| Previous MI | 148(9.0%) | 77(9.3%) | 71(8.6%) | 0.605 |
| Previous PCI | 158(9.6%) | 86(10.4%) | 72(8.7%) | 0.241 |
| Previous stroke | 321(19.5%) | 157(19.0%) | 164(19.9%) | 0.663 |
| Previous PAD | 260(15.8%) | 119(14.4%) | 141(17.1%) | 0.137 |
| Laboratory results | ||||
| WBC (×109/L) | 7.30 ± 2.57 | 7.14 ± 2.58 | 7.46 ± 2.54 | 0.013 |
| PLT (×109/L) | 158.49 ± 55.42 | 156.37 ± 53.36 | 160.61 ± 57.35 | 0.120 |
| Hb (g/L) | 138.15 ± 18.40 | 136.79 ± 18.41 | 139.51 ± 18.30 | 0.003 |
| BUN (mmol/L) | 5.29 ± 1.83 | 5.13 ± 1.93 | 5.46 ± 1.70 | < 0.001 |
| Cr (umol/L) | 67.93 ± 17.72 | 67.81 ± 18.22 | 68.05 ± 17.21 | 0.779 |
| eGFR (mL/min/1.73m2) | 97.48 ± 27.25 | 96.98 ± 26.14 | 97.98 ± 28.34 | 0.455 |
| FBG (mmol/L) | 5.92 ± 1.85 | 5.19 ± 1.24 | 6.64 ± 2.07 | < 0.001 |
| HbA1C (%) | 5.61 ± 0.64 | 5.49 ± 0.54 | 5.74 ± 0.70 | < 0.001 |
| HDL-C (mmol/L) | 0.98 ± 0.23 | 1.00 ± 0.23 | 0.95 ± 0.22 | < 0.001 |
| TC (mmol/L) | 3.71 ± 1.17 | 3.41 ± 1.09 | 4.01 ± 1.16 | < 0.001 |
| TG (mmol/L) | 1.52 ± 0.90 | 1.07 ± 0.33 | 1.98 ± 1.05 | < 0.001 |
| LDL-C (mmol/L) | 1.82 ± 0.85 | 1.67 ± 0.70 | 1.96 ± 0.95 | < 0.001 |
| NT-proBNP (pg/mL) | 690.55 ± 1233.19 | 729.52 ± 1239.91 | 651.57 ± 1225.95 | 0.199 |
| LVEF (%) | 60.07 ± 11.28 | 59.99 ± 11.21 | 60.16 ± 11.36 | 0.760 |
| Angiographic data | ||||
| LM disease, n (%) | 174(10.5%) | 88(10.7%) | 86(10.4%) | 0.873 |
| CTO, n (%) | 475(28.8%) | 243(29.5%) | 232(28.8%) | 0.550 |
| Number-vessel disease. n (%) | 0.574 | |||
| Single-vessel disease | 445(27.0%) | 231(28.0%) | 214(25.9%) | |
| Two-vessel disease | 497(30.1%) | 249(30.2%) | 248(30.1%) | |
| Three-vessel disease | 708(42.9%) | 345(41.8%) | 363(44.0%) | |
| Diffuse lesion, n (%) | 985(59.7%) | 506(61.3%) | 479(58.1%) | 0.175 |
| In-stent restenosis, n (%) | 48(2.9%) | 27(3.3%) | 21(2.5%) | 0.379 |
| Calcification lesion, n (%) | 38(2.3%) | 18(2.2%) | 20(2.4%) | 0.743 |
| Number of stents | 1.71 ± 1.15 | 1.68 ± 1.11 | 1.74 ± 1.20 | 0.276 |
| Medication at discharge, n (%) | ||||
| ACEI/ARB | 1345(81.5%) | 664(80.5%) | 681(82.5%) | 0.281 |
| β-blocker | 1338(81.1%) | 663(80.4%) | 675(81.8%) | 0.451 |
| Statins | 1643(99.6%) | 824(99.9%) | 819(99.3%) | 0.124 |
| P2Y12 inhibitor | 0.934 | |||
| Clopidogrel | 1491(90.4%) | 746(90.4%) | 745(90.3%) | |
| Ticagrelor | 159(9.6%) | 79(9.6%) | 80(9.7%) | |
| Aspirin | 1650(100.0%) | 825(100%) | 825(100%) | – |
| DAPT | 1650(100.0%) | 825(100%) | 825(100%) | – |
TyG, triglyceride-glucose; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; CAD, coronary artery disease; UA, unstable angina; NSTEMI, non ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction; MI, myocardial infarction; PCI, percutaneous coronary intervention; PAD, peripheral artery disease; WBC, white blood cell; PLT, platelet; Hb, hemoglobin; BUN, blood urea nitrogen; Cr, creatinine; eGFR, estimated glomerular filtration rate; FBG, fasting blood glucose; HbA1C, glycosylated hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; TC, total cholesterol; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol; LVEF, left ventricular ejection fraction; LM, left main; CTO, chronic total occlusion; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; DAPT, dual antiplatelet therapy.